Inhibitor Therapeutics, Inc. (INTI)
| Previous close | 0.0858 |
| Open | 0.0858 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0858 - 0.0858 |
| 52-week range | 0.0130 - 0.3000 |
| Volume | |
| Avg. volume | 8,923 |
| Market cap | 14.76M |
| Beta (5Y monthly) | -0.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireIntroducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
At the forefront of the Inhibitor Therapeutics, Inc. (OTCQB:INTI) pipeline is the use of Itraconazole to treat basal cell carcinomas in Basal Cell Carcinoma Nevus Syndrome (BCCNS) aka Gorlin Syndrome. This rare hereditary cancer syndrome is characterized by patients with hundreds to thousands of basal cell carcinomas. BCCNS is an orphan disease with approximately 11,000 patients in the USA. It is an autosomal dominant disorder that may affect every organ system.
PR NewswireInhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors". Angiogenesis Inhibitors, as described by the National Cancer Institute, are unique cancer fighting agents as they block the growth of blood vessels that support tumor growth rather than blocking the growth of the tumor cells themselves. Inven
